

Pharmacophore

(An International Research Journal)

Available online at <http://www.pharmacophorejournal.com>

Original Research Paper

SYNTHESIS AND MICROBIOLOGICAL EVALUATION OF SOME NEW BISCHALCONES

Asif Husain^{1*}, Saleem Javed², Ravinesh Mishra¹, Mohd Rashid¹ and Rubina Bhutani¹

¹ Department of Pharmaceutical Chemistry, Faculty of Pharmacy,
Jamia Hamdard (Hamdard University),
New Delhi-110 062, India

² Department of Biochemistry, Faculty of Science,
Jamia Hamdard (Hamdard University),
New Delhi-110 062, India

ABSTRACT

A series of bischalcones (4a-j) were synthesized and evaluated for their antimicrobial actions. Bischalcones were prepared by condensing 1,1'-(4,6-dimethyl-1,3-phenylene)diethanone (3) with appropriate aromatic aldehydes in ethanol in presence of KOH. The structures of the synthesized compounds were confirmed on the basis of ¹H NMR, Mass and elemental analysis results. The antimicrobial screening of the title compounds was performed at a concentration of 100 µg/mL by cup plate method; the compounds inhibiting growth of one or more of the microorganisms were further tested for their minimum inhibitory concentration (MIC) by turbidity method. The results revealed that the compound 4f showed good activity against *S. aureus*, *E. coli* and *P. aeruginosa* with MIC-12.5 µg/mL. Similar type of activity was shown by the compound 4g against *S. aureus* and *E. coli* and, by the compound 4j against *S. aureus* and *P. aeruginosa* with MIC-12.5 µg/mL.

Keywords: Bischalcone, MIC, Antibacterial, Antifungal.

INTRODUCTION

The increasing incidence of resistance to a number of antibacterial agents is becoming a major concern^{1,2}. Moreover, incidences of systemic bacterial and fungal infections are increasing due to an increase in the number of immuno-compromised hosts.

Immunosuppression due to malignancy, immunosuppressive therapies, HIV-infection, broad-spectrum antimicrobial treatment and age, places patients at risk for microbial infections. A

small number of antifungal agents are available in the market, and all have some drawbacks regarding their spectrum^{3,4}, tissue distribution, toxicity, and high cost. Therefore the need of hour is to search for alternative new and more effective antimicrobial agents with a broad spectrum activity. Among a wide variety of compounds that have been explored for developing antimicrobial agents, Flavonoidal derivatives-chalcones, flavanones and flavones have played an important role⁵⁻⁹. Chalcones have attracted considerable attention due to their

marked physiological activity and distinct functions. They form a large group of naturally occurring organic compounds and possess wide range of pharmacological actions including antimicrobial action⁵⁻¹⁴. Also, chalcone derivatives acquire a special place in natural chemistry as well as in heterocyclic chemistry because this system is a frequently encountered structural motif in many pharmacologically relevant compounds¹⁵⁻¹⁸.

Resorcinol is a simple and important aromatic moiety (1,3-benzenediol) that has been chemically incorporated into various compounds to improve their pharmacological profile¹⁹⁻²¹. In view of these points it was considered worthwhile to study some resorcinol-based bischalcones derivatives for their antimicrobial actions.

MATERIALS AND METHODS

Chemistry

Melting points are uncorrected and were recorded in liquid paraffin bath using open end capillaries. ¹H-NMR spectra were recorded on Bruker spectropsin DPX-300 MHz in CDCl₃; chemical shift (δ) values are reported in parts per million (*ppm*). The splitting pattern abbreviations are as follows: s, singlet; d, doublet; dd, double doublet; m, multiplet. Mass spectroscopic analyses for compounds were performed on a JEOL JMS-D 300 instrument. Elemental analyses were performed on a Perkin-Elmer 240 analyzer and were in range of $\pm 0.4\%$ for each element analyzed (C, H, N). Thin-layer chromatography was carried out to monitor the reactions using silica gel G as stationary phase and iodine chamber and UV lamp were used for visualization of TLC spots.

Synthesis of 1,1'-(4,6-Dihydroxy-1,3-phenylene)diethanone (2)

It was prepared from resorcinol (**1**) following literature method¹⁹. It gave a violet colour with ethanolic ferric chloride solution; positive test for phenols. Yield 72%; m.p. 184-186°C. ¹H

NMR (CDCl₃, δ , ppm): 2.65 (s, 6H, 2 \times -COCH₃), 6.65 (s, 1H, H-2), 8.15 (s, 1H, H-5).

Synthesis of 1-(5-acetyl-2,4-dimethoxyphenyl)-1-ethanone (3)

A mixture of 1,1'-(4,6-dimethyl-1,3-phenylene)diethanone (**2**) (2.5 mmol), dimethylsulphate (5 mmol) and anhydrous potassium carbonate (11.25 g) in dry acetone (100 mL) was refluxed for 6 h. The contents were then filtered, concentrated to a small volume and poured onto crushed ice. A solid mass separated out which was filtered, washed with water, dried and then crystallized from methanol:dichloromethane mixture to give shiny needles of **3** (it did not give violet colour with ethanolic ferric chloride solution; negative test for phenols). Yield 74%, m.p. 164-166°C. ¹H NMR (CDCl₃) δ 2.61 (s, 6H, 2 \times -COCH₃), 3.93 (s, 6H, 2 \times -OCH₃), 6.34 (s, 1H, H-2), 8.37 (s, 1H, H-5). MS: *m/z* 222 (M⁺), 207, 177, 175, 149. Anal calcd. for C₁₂H₁₄O₄: C, 64.85; H, 6.35. Found: C, 64.71; H, 6.22.

*General procedure for synthesis of Bischalcones (4a-j)*²²

A mixture of compound **3** (5 mmol) in ethanol (20 mL), an aromatic aldehyde (10 mmol) and a solution of potassium hydroxide (3 g) in distilled water (5 mL) was stirred for 2 h at room temperature and then left overnight. It was poured into cold water and acidified with HCl, a solid mass separated out which was filtered, washed with water, sodium bicarbonate solution (2% w/v in water) and again with water. It was crystallized to give **4a-k** (It gave a red colour with conc. sulphuric acid; positive test for chalcones, and no colour with ethanolic ferric chloride solution; negative test for phenols).

1-(2,4-Dimethoxy-5-[3-(3-nitrophenyl)acryloyl]phenyl)-4-(3-nitrophenyl)but-2-en-1-one 4a

Yield: 61%, m.p. 220-222°C. ¹H NMR (CDCl₃) δ 3.98 (s, 6H, 2 \times -OCH₃), 6.54 (s, 1H, H-3'), 7.26

(d, 2H, 2xH- α), 7.58 (m, 2H, 2xH-5), 7.87 (dd, 2H, 2xH-4), 8.05 (d, 2H, 2xH- β), 8.26 (dd, 2H, 2xH-6), 8.20 (s, 1H, H-6'), 8.43 (s, 2H, 2xH-2). MS: m/z 488 (M^+), 340, 312, 176, 136. Anal calcd. for $C_{26}H_{20}N_2O_8$: C, 63.93; H, 4.13; N, 5.74. Found: C, 63.81; H, 4.06; N, 5.50.

1-(2,4-Dimethoxy-5-[3-(4-nitrophenyl)acryloyl]phenyl)-4-(4-nitrophenyl)but-2-en-1-one 4b

Yield: 65%, m.p. 234-236°C. 1H NMR ($CDCl_3$) δ 4.02 (s, 6H, 2x-OCH₃), 6.55 (s, 1H, H-3'), 7.04-7.46 (m, 6H, 2xH-3,5, α), 7.78-8.13 (m, 6H, 2xH-2,6,H- β), 8.22 (s, 1H, H-6'). MS: m/z 488 (M^+), 340, 176, 148. $C_{26}H_{20}N_2O_8$: C, 63.93; H, 4.13; N, 5.74. Found: C, 63.71; H, 4.12; N, 5.46.

1-(2,4-Dimethoxy-5-[3-(2-chlorophenyl)acryloyl]phenyl)-4-(2-chlorophenyl)but-2-en-1-one 4c

Yield: 58%, m.p. 202-204°C. 1H NMR ($CDCl_3$) δ 3.96 (s, 6H, 2x-OCH₃), 6.51 (s, 1H, H-3'), 7.06-7.34 (m, 4H, 2xH-3,5), 7.41-7.53 (m, 6H, 2xH-4,6, α), 7.88 (d, 2H, 2xH- β), 8.19 (s, 1H, H-6'). MS: m/z 466 (M^+), 330, 267, 131. Anal calcd. for $C_{26}H_{20}Cl_2O_4$: C, 66.82; H, 4.31. Found: C, 66.56; H, 4.64.

1-(2,4-Dimethoxy-5-[3-(4-chlorophenyl)acryloyl]phenyl)-4-(4-chlorophenyl)but-2-en-1-one 4d

Yield: 62%, m.p. 195-196°C. 1H NMR ($CDCl_3$) δ 3.89 (s, 6H, 2x-OCH₃), 6.53 (s, 1H, H-3'), 6.86 (d, 4H, 2xH-3,5), 7.23 (d, 2H, 2xH- α), 7.49 (d, 4H, 2xH-2,6), 7.78 (d, 2H, 2xH- β), 8.18 (s, 1H, H-6'). MS: m/z 466 (M^+), 302, 295, 131. Anal calcd. for $C_{26}H_{20}Cl_2O_4$: C, 66.82; H, 4.31. Found: C, 66.74; H, 4.57.

1-(2,4-Dimethoxy-5-[3-(2-methylphenyl)acryloyl]phenyl)-4-(2-methylphenyl)but-2-en-1-one 4e

Yield: 54%, m.p. 188-190°C. 1H NMR ($CDCl_3$) δ 2.42 (s, 6H, 2x-CH₃), 3.95 (s, 6H, 2x-OCH₃),

6.39 (s, 1H, H-3'), 6.81-7.47 (m, 8H, 2xH-3,4,5,6), 7.50 (d, 2H, 2xH- α), 7.98 (d, 2H, 2xH- β), 8.16 (s, 1H, H-6'). MS: m/z 426 (M^+), 309, 281, 145, 117, 105. Anal calcd. for $C_{28}H_{26}O_4$: C, 78.85; H, 6.14. Found: C, 78.66; H, 6.25.

1-(2,4-Dimethoxy-5-[3-(4-hydroxy-3-methoxyphenyl)acryloyl]phenyl)-4-(4-hydroxy-3-methoxyphenyl)but-2-en-1-one 4f

Yield: 61%, m.p. 208-209°C. 1H NMR ($CDCl_3$) δ 3.92 (s, each, 6H, 2x-OCH₃), 3.98 (s, each, 6H, 2x-OCH₃), 6.48 (s, 1H, H-3'), 6.87 (d, 2H, 2xH-5), 7.16-7.23 (m, 4H, 2xH-2,6), 7.36 (d, 2H, 2xH- α), 7.64 (d, 2H, 2xH- β), 8.18 (s, 1H, H-6'). MS: m/z 490 (M^+), 341, 295, 103, 91. Anal calcd. for $C_{28}H_{26}O_8$: C, 68.56; H, 5.34. Found: C, 68.42; H, 5.31.

1-(2,4-Dimethoxy-5-[3-(2,6-dichlorophenyl)acryloyl]phenyl)-4-(2,6-dichlorophenyl)but-2-en-1-one 4g

Yield: 58%, m.p. 180-182°C. 1H NMR ($CDCl_3$) δ 3.96 (s, 6H, 2x-OCH₃), 6.51 (s, 1H, H-3'), 7.22-7.36 (m, 4H, 2xH-4 + 2xH- α), 7.48-7.56 (m, 4H, 2xH-3,5), 7.88 (d, 2H, 2xH- β), 8.15 (s, 1H, H-6'). MS: m/z 550 (M^+), 293, 267, 131. Anal calcd. for $C_{27}H_{20}Cl_4O_4$: C, 58.93; H, 3.66. Found: C, 59.28; H, 3.46.

1-(2,4-Dimethoxy-5-[3-(2-hydroxyphenyl)acryloyl]phenyl)-4-(2-hydroxyphenyl)but-2-en-1-one 4h

Yield: 54%, m.p. 221-222°C. 1H NMR ($CDCl_3$) δ 3.93 (s, 6H, 2x-OCH₃), 6.45 (s, 1H, H-3'), 6.99-7.53 (m, 10H, 2xH-3,4,5,6, α), 7.82 (d, 2H, 2xH- β), 8.17 (s, 1H, H-6'). MS: m/z 430 (M^+), 311, 295, 103, 91. Anal calcd. for $C_{26}H_{22}O_6$: C, 72.55; H, 5.15. Found: C, 72.40; H, 5.20.

1-(2,4-Dimethoxy-5-[3-(3-hydroxyphenyl)acryloyl]phenyl)-4-(3-hydroxyphenyl)but-2-en-1-one 4i

Yield: 51%, m.p. 214-215°C. 1H NMR ($CDCl_3$) δ 3.95 (s, 6H, 2x-OCH₃), 6.50 (s, 1H, H-3'), 7.26

(d, 2H, 2xH- α), 7.31-7.36 (m, 2H, 2xH-5), 7.67 (dd, 2H, 2xH-4), 7.88 (d, 2H, 2xH- β), 7.98 (dd, 2H, 2xH-6), 8.18 (s, 1H, H-6'), 8.26 (s, 2H, 2xH-2). MS: m/z 430 (M^+), 309, 295, 103, 91. Anal calcd. for $C_{26}H_{22}O_6$: C, 72.55; H, 5.15. Found: C, 72.48; H, 5.08.

1-(2,4-Dimethoxy-5-[3-(4-fluorophenyl)acryloyl]phenyl)-4-(4-fluorophenyl)but-2-en-1-one (4j)

Yield: 60%, m.p. 196-198°C. 1H NMR ($CDCl_3$) δ 3.89 (s, 6H, 2x-OCH₃), 6.48 (s, 1H, H-3'), 7.03-7.84 (m, 12H, 2xH-2,3,5,6, α , β), 8.12 (s, 1H, H-6'). MS: m/z 434 (M^+), 313, 285, 149, 131, 77. Anal calcd. for $C_{26}H_{20}F_2O_4$: C, 71.88; H, 4.64. Found: C, 71.96; H, 4.41.

Microbiology

The synthesized compounds were evaluated for their antimicrobial activity^{23,24} against three bacterial strains and two fungal strains at a concentration of 100 μ g/mL by cup plate method. Compounds inhibiting growth of one or more of the test microorganisms were further tested for their minimum inhibitory concentration (MIC).

Antibacterial Activity

The compounds were screened for their antibacterial activity against *Staphylococcus aureus* (ATCC-25923), *Escherichia coli* (ATCC-25922), and *Pseudomonas aeruginosa* (ATCC-27853) bacterial strains at a concentration of 100 μ g/mL by cup plate method²³. Ciprofloxacin was used as standard drug for comparison. Freshly prepared liquid agar medium (25 mL/petridish) was poured into each petridishes and the plates were dried by placing in an incubator at 37°C for 1 h. Then standardized culture of microorganism was spread on each petridishes by L-shaped spreader. Wells (6 mm) were made using an agar punch and, each well was labeled accordingly. A control (solvent) was also included in the test. The test compound and standard drug solutions (100 μ g/mL) were made in dimethylsulfoxide

(DMSO) and added in each well separately and petridishes kept aseptically for 1h for diffusion of the sample. After the completion of diffusion, all the petridishes were kept for incubation at 37°C for 24 h and then diameter of the zone of inhibition was measured in mm (Table 1).

Compounds inhibiting growth of one or more of the test microorganisms were further tested for their minimum inhibitory concentration (MIC) by broth dilution technique. A solution of the compounds (100 μ g/mL) was prepared in DMSO and a series of doubling dilutions prepared with sterile pipettes. To each of a series of sterile test tubes a standard volume of nutrient broth medium was added. A control tube containing no antimicrobial agent was included. The inoculum consisting of an overnight broth culture of microorganisms was added to separate tubes. The tubes were incubated at 37° for 24 h and examined for turbidity. The highest dilution (lowest concentration) required to stop the growth of bacteria was regarded as MIC. Results are presented in Table 2.

Antifungal Activity

Antifungal activity of the synthesized compounds was determined against *Candida albicans* (ATCC-10231) and *Aspergillus niger* (ATCC-16404) by agar diffusion method²³. Sabourands agar media was prepared by dissolving peptone (1 g), D-glucose (4 g) and agar (2 g) in distilled water (100 mL) and adjusting pH to 5.7. Normal saline was used to make a suspension of spore of fungal strain for lawning. A loopful of particular fungal strain was transferred to 3 mL saline to get a suspension of corresponding species. Agar media (20 mL) was poured into each petridish and the plates were dried by placing in an incubator at 37°C for 1 h. Wells were made using an agar punch and, each well was labeled accordingly. A control was also prepared in triplicate and maintained at 37°C for 3-4 days. The test compounds and standard drug (Griseofulvin) solutions (100 μ g/mL) were made

in dimethylsulfoxide (DMSO) and added in each well separately and petridishes kept aseptically for 1h for diffusion of the sample. After the completion of diffusion, all the petridishes were kept for incubation at 37°C for 3-4 days and then diameter of the zone of inhibition was measured in mm (Table 1). Compounds inhibiting growth of one or more of the fungal strains were further tested for their minimum inhibitory concentration (MIC). A solution of the compounds (100 µg/mL) was prepared in DMSO and a series of doubling dilutions prepared with sterile pipettes. To each of a series of sterile test tubes a standard volume of nutrient broth medium was added. A control tube containing no antimicrobial agent was included. The tubes were inoculated with approximately 1.6×10^4 - 6×10^4 c.f.u. mL⁻¹ and incubated for 48 h at 37°C and examined for growth. The lowest concentration (highest dilution) required to arrest the growth of fungus was regarded as MIC. Results are presented in Table 2.

RESULTS AND DISCUSSION

Chemistry

The protocol for synthesis of title compounds is presented in Scheme-1. The starting material, 1,1'-(4,6-dihydroxy-1,3-phenylene)diethanone (2), prepared from resorcinol (1), was treated with dimethylsulphate in dry acetone in presence of anhydrous potassium carbonate to get 1,1'-(4,6-dimethyl-1,3-phenylene)diethanone (3), which gave negative ferric chloride test showing the absence of phenolic-hydroxyl group. Compound (3) was then condensed with different aromatic aldehydes in presence of potassium hydroxide following Claisen-Schmidt reaction conditions²² to furnish 10 new bischalcones (4a-j). These compounds gave a red colour with conc. sulphuric acid; positive test for chalcones, and no colour with ethanolic ferric chloride solution; negative test for phenolic-hydroxyl group. The structures of the synthesized compounds were further supported by ¹H NMR, Mass spectral data and elemental analysis results.

The ¹H NMR spectrum of 1,1'-(4,6-dimethyl-1,3-phenylene)diethanone (3) showed a singlet at δ 2.61, which could be accounted for six protons of two acetyl groups. The two methoxyl groups appeared as singlet at δ 3.93. The ring protons, H-2 and H-5, gave singlet at δ 6.34 and 8.37, respectively. The mass spectrum of the compound (3) showed a peak at *m/z* 222, which was the molecular ion of the compound, other peaks were observed at *m/z* 207, 177, 175 and 149. The proposed fragmentation pattern has been presented in Chart 1.

The ¹H NMR spectra of the title bischalcones (4a-j) revealed the presence of two methoxyl groups as singlet at around δ 3.9, and two -CH=CH- groups as two doublets at around δ 7.3 and δ 8.0 integrating for two CH-α and two CH-β protons, respectively. Chalcone ring protons H-3' & H-6' appeared as singlet at δ 6.5 and δ 8.2, respectively. Other signals were observed at appropriate δ values integrating for the protons of two substituted phenyl rings. The mass spectra of bischalcones showed the presence of molecular ion peaks in reasonable intensities. The observed fragmentation pattern of bischalcones (4a-j) is presented in Chart 2. Elemental analyses values of the synthesized compounds were found within ±0.4% of theoretical values.

Antibacterial and Antifungal Activity

The newly prepared compounds were screened for their antibacterial activity against *Staphylococcus aureus* (ATCC-25923), *Escherichia coli* (ATCC-25922) and *Pseudomonas aeruginosa* (ATCC-27853) bacterial species, and antifungal activity against *Candida albicans* (ATCC-10231) and *Aspergillus niger* (ATCC-16404). The antimicrobial screening data showed that compounds 4f, 1-(2,4-dimethoxy-5-[3-(4-hydroxy-3-methoxyphenyl)acryloyl]phenyl)-4-(4-hydroxy-3-methoxyphenyl)but-2-en-1-one, exhibited good activity against *S. aureus*, *E. coli* & *P. aeruginosa* with MIC-12.5 µg/mL. Similar type of activity was shown by the compound 4g,

1-(2,4-dimethoxy-5-[3-(2,6-dichlorophenyl)acryloyl]phenyl)-4-(2,6-chlorophenyl)but-2-en-1-one, against *S. aureus* & *E. coli*, and by the compound 4j, 1-(2,4-dimethoxy-5-[3-(4-fluorophenyl)acryloyl]phenyl)-4-(4-fluorophenyl)but-2-en-1-one, against *S. aureus* & *P. aeruginosa* with MIC-12.5 µg/mL. Another compound, Compounds 4d, 1-(2,4-dimethoxy-5-[3-(4-chlorophenyl)acryloyl]phenyl)-4-(4-chlorophenyl)but-2-en-1-one, was active against *S. aureus* with MIC-12.5 µg/mL. Rest of the compounds showed moderate to low antimicrobial activities. The standard drugs showed MIC values of 6.25 µg/mL (Table 1 & 2).

An analysis of results indicated that the bischalcones 4a-j were appreciable in their antibacterial and antifungal actions. Presence of chloro or fluoro group(s) increased the antimicrobial activity of the bischalcones.

CONCLUSION

10 New bischalcones derivatives (4a-j) were successfully synthesized starting from resorcinol. The antimicrobial studies showed that the synthesized compounds were having appreciable antibacterial and antifungal activities. 1-(2,4-dimethoxy-5-[3-(4-hydroxy-3-methoxyphenyl)acryloyl]phenyl)-4-(4-hydroxy-3-methoxyphenyl)but-2-en-1-one (4f) emerged as lead compound among the synthesized compounds. Presence of chloro or fluoro group(s) increased the antimicrobial activity of the bischalcones. It is conceivable that the derivatives showing significant anti-microbial activity can be further modified to exhibit better potency than the standard drugs.

ACKNOWLEDGEMENT

The authors are thankful to IIT-Delhi for spectral studies. Help provided by Prof. P.K. Pillai, Department of Microbiology, Majeedia Hospital, New Delhi, is gratefully acknowledged.

Table 2: Antibacterial and antifungal activities (MIC, µg/mL) of the title compounds

Compd.	Substituent (R)	Antibacterial activity			Antifungal activity	
		<i>S. aureus</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>C. albicans</i>	<i>A. niger</i>
4a	3-Nitro	>100	>100	50	50	>100
4b	4-Nitro	50	>100	50	50	50
4c	2-Chloro	25	25	50	25	50
4d	4-Chloro	12.5	25	25	25	>100
4e	2-Methyl	>100	>100	>100	>100	>100
4f	4-Hydroxy-3-methoxy	12.5	12.5	12.5	25	25
4g	2,6-Dichloro	12.5	12.5	25	25	>100
4h	2-Hydroxy	50	50	25	50	>100
4i	3-Hydroxy	>100	>100	50	>100	50
4j	4-Fluoro	12.5	25	12.5	25	50
Standard-1†		6.25	6.25	6.25	nt	nt
Standard-2†		nt	nt	nt	6.25	6.25

nt = not tested; †Standard-1 = Ciprofloxacin, Standard-2 = Griseofulvin.

REFERENCES

- Davies, J (1996), "Bacteria on the rampage", *Nature*, 383, 219-220.
- Chu, DTW; Plattner, JJ; Katz, L (1996), "New directions in antibacterial research", *J. Med. Chem.* 39, 3853-3874.
- Dupont, B; Kontoyiannis, DP; Lewis, RE (2002), "Antifungal drug resistance of pathogenic fungi", *Lancet*, 359(9312), 1135-1144.
- Baddley, JW; Moser, SA (2004), "Emerging fungal resistance", *Clin. Lab. Med.*, 24, 721.
- Cushnie, TP; Lamb, AJ (2005), "Antimicrobial activity of flavonoids", *Int. J. Antimicrob. Agents*, 26, 343-356.
- Nowakowska, Z (2007), "A review of anti-infective and anti-inflammatory chalcones", *Eur. J. Med. Chem.*, 42, 125-137.
- Lin, YM; Zhou, Y; Flavin, MT; Zhou, LM; Nie, W; Chen, FC (2002), "Chalcones and flavonoids as anti-tuberculosis agents", *Bioorg. Med. Chem.*, 10, 2795-2802.
- Batovska, DI; Todorova, IT (2010), "Trends in utilization of the pharmacological potential of chalcones", *Curr. Clin. Pharmacol.*, 5, 01-29.
- Sharma, M; Chaturvedi, V; Manju, YK; Bhatnagar, S; Srivastava, K; Puri, SK; Chauhan, PM (2009), "Substituted quinolinyl chalcones and quinolinyl pyrimidines as a new class of anti-infective agents", *Eur. J. Med. Chem.*, 44, 2081-2091.
- Casano, G; Dumetre, A; Pannecouque, C; Hutter, S; Azas, N; Robin, M (2010), "Anti-HIV and antiplasmodial activity of original flavonoid derivatives", *Bioorg. Med. Chem.*, 18, 6012-6023.

11. Liu, HL; Jiang, WB; Xie, MX (2010), "Flavonoids: recent advances as anticancer drugs", *Recent Patents Anticancer Drug Discov.*, 5, 152-164.
12. Mojzis, J; Varinska, L; Mojzisova, G; Kostova, I; Mirossay, L (2008), "Antiangiogenic effects of flavonoids and chalcones", *Pharmacol. Res.*, 57, 259-265.
13. Alvim, JJ; Severino, RP; Marques, EF; Martinelli, AM; Vieira, PC; Fernandes, JB; Silva, MF; Correa, AG (2010), "Solution phase synthesis of a combinatorial library of chalcones and flavones as potent cathepsin V inhibitors", *J. Comb. Chem.*, 12, 687-695.
14. Boumendié, A; Ronot, X; Boutonnat, J (2009), "Chalcones derivatives acting as cell cycle blockers: potential anti cancer drugs?", *Curr Drug Targets*, 10, 363-371.
15. Alcaraz, LE; Blanco, SE; Puig, ON; Tomas, F; Ferretti, FH (2000), "Antibacterial activity of flavonoids against methicillin-resistant *Staphylococcus aureus* strains", *J. Theor. Biol.*, 205, 231-240.
16. Mojzis, J; Varinska, L; Mojzisova, G; Kostova, I; Mirossay, L (2008), "Antiangiogenic effects of flavonoids and chalcones", *Pharmacol. Res.*, 57, 259-265.
17. Sherif, BAG; Louise, W; Zidan, HZ; Hussein, MA; Keevil, CW; Brown, RCD (2008), "Microwave-assisted synthesis and antimicrobial activities of flavonoid derivatives", *Bioorg. Med. Chem. Lett.*, 18, 518-522.
18. Alvarez, MA; Debattista, NB; Pappano, NB (2008), "Antimicrobial activity and synergism of some substituted flavonoids", *Folia Microbiol.*, 53, 23-28.
19. Khan, MSY; Sharma, S; Husain, A (2002), "Synthesis and antibacterial evaluation of new flavonoid derivatives from 4,6-diacetyl resorcinol", *Scientia Pharmaceutica*, 70, 287-294.
20. Soliman, K; Ohad, N; Ramadan, M; Maayan, S; Snait, T; Jacob, V (2005), "Chalcones as potent tyrosinase inhibitors: the importance of a 2,4-substituted resorcinol moiety", *Bioorg. Med. Chem.*, 13, 433-441.
21. Khan, MSY; Husain, A; Sharma, S (2010), "New 4,6-Diacetyl resorcinol Mannich bases: Synthesis and biological evaluation", *Acta Poloniae Pharmaceutica (Drug Research)* 67, 261-266.
22. Dhar, DN (1981), "*The Chemistry of Chalcones and Related Compounds*", John Wiley & Sons, New York, 05.
23. Colle, JG; Duguid, JP; Fraser, AG; Marmion, BP (1989), "Laboratory strategies in diagnosis", In: Mackie TJ, MacCartney JE, eds. *Practical Medical Microbiology*, 13th ed, London, Churchill-Livingstone, 601-649.
24. Varma, RS (1998), "*Antifungal Agents: Past, Present and Future Prospects*", National Academy of Chemistry & Biology, Lucknow, India.